Meriofert

Luteinising hormone (human), Follicle‑stimulating hormone, the active ingredient in Meriofert, is a gonadotropin presented as an injectable solution for intramuscular and subcutaneous use. It is indicated for infertility caused by hypogonadotropic hypogonadism and for stimulating follicular development in assisted reproductive technology such as IVF.

GNH USA supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with the product sourced from the European Union market and adheres to stringent quality standards.

Meriofert, a gonadotropin used in reproductive endocrinology, is employed to address specific infertility conditions.

Infertility due to hypogonadotropic hypogonadism: restores endogenous gonadal hormone production to enable ovulation or spermatogenesis. Assisted reproductive technology (IVF): stimulates follicular development to obtain multiple oocytes for retrieval. Ovulation induction in anovulatory women: promotes follicular growth leading to ovulation.

Common Side Effects: - Injection site pain or erythema. - Mild abdominal discomfort or bloating. - Nausea or headache. - Transient fluid retention.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome, potentially severe. - Multiple pregnancy. - Allergic reactions including anaphylaxis. - Severe abdominal pain indicating possible ovarian torsion. - Thromboembolic events.

Precautions for Meriofert include careful patient monitoring and adherence to handling guidelines. - Monitor ovarian response: perform serial ultrasound and estradiol assessments. - Avoid use in uncontrolled thyroid disease: assess thyroid function before initiation. - Assess for pituitary adenomas: evaluate pituitary status when indicated. - Use caution in patients with thromboembolic risk: consider prophylactic measures. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert may interact with other medications affecting reproductive hormone pathways.

Major Interactions (Avoid): - GnRH antagonists: may blunt the therapeutic response. - High‑dose estrogen therapy: can interfere with gonadotropin efficacy.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may alter baseline hormone levels; discontinue before treatment. - Thyroid hormone replacement: monitor thyroid status during therapy. - Diuretics: may affect fluid balance; observe for signs of dehydration.